



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Demo Report

Report Issued 03/30/2020 11:54
Last Report Issued 08/04/2010 06:47

88888
Clinical Example Report
Attn: Example Reports
200 Welsh Road
Horsham, PA 19044

Patient Name 1287SP-POS
Patient ID 1287SP-POS
Chain 10001608
Age Not Given **DOB** Not Given
Gender Not Given
Workorder 10001608
Received 08/04/2010 06:42

Sample ID 10001608-001
Matrix Serum or Plasma
Patient Name 1287SP-POS
Patient ID 1287SP-POS
Container Type Clear vial

Collect Dt/Tm Not Given
Source Not Given

Approx Vol/Weight Not Given

Receipt Notes None Entered

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

1287SP Clozapine and Metabolite, Serum/Plasma

Analysis by High Performance Liquid Chromatography/
Tandem Mass Spectrometry (LC-MS/MS)

Clozapine	50	ng/mL	20	
-----------	----	-------	----	--

Synonym(s): Clozaril®

After typical therapeutic doses of Clozapine, plasma concentrations are reported to range from 60 - 1000 ng/mL, with average concentrations between 200 - 400 ng/mL.

At an average dose of 3.09 mg/Kg, steady-state plasma concentrations of Clozapine averaged 231 ng/mL +/- 144 ng/mL (mean +/- SD). Norclozapine concentrations averaged 84% of Clozapine.

Norclozapine	50	ng/mL	20	
--------------	----	-------	----	--

Synonym(s): Clozapine Metabolite

Results for sample 10001608-001 are continued on next page



NMS Labs

CONFIDENTIAL

200 Welsh Road, Horsham, PA 19044-2208
Phone: (215) 657-4900 Fax: (215) 657-2972
e-mail: nms@nmslabs.com

Robert A. Middleberg, PhD, F-ABFT, DABCC-TC, Laboratory Director

Sample ID 10001608-001
Matrix Serum or Plasma
Patient Name 1287SP-POS
Patient ID 1287SP-POS

Collect Dt/Tm Not Given
Source Not Given

Analysis and Comments	Result	Units	Reporting Limit	Notes
-----------------------	--------	-------	-----------------	-------

The rate of formation and biologic activity of Clozapine metabolites have not been fully elucidated. One study of patients dosed with 400 mg Clozapine daily for 4 weeks showed that patients were most likely to respond to therapy when plasma concentrations of Clozapine plus Norclozapine (limited activity) totaled at least 450 ng/mL.

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.